To evaluate the feasibility of obtaining a 21-gene Oncotype DX Breast Recurrence ScoreÂ® (RS) result from metastatic biopsies in newly diagnosed hormone receptor positive, HER2- metastatic breast cancer patients and correlate RS results with matched primary samples.
